Ajanta Pharma Limited (NSE:AJANTPHARM)
India flag India · Delayed Price · Currency is INR
2,968.60
+10.80 (0.37%)
Feb 18, 2026, 1:30 PM IST

Ajanta Pharma Ratios and Metrics

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Feb '26 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
369,393327,581280,899154,878154,667155,056
Market Cap Growth
12.55%16.62%81.37%0.14%-0.25%30.05%
Enterprise Value
362,451320,489276,473149,016149,244150,485
Last Close Price
2957.802593.902186.251153.991145.991129.13
PE Ratio
36.4235.5934.4226.3421.7023.71
Forward PE
30.8931.5331.0320.5219.5523.58
PS Ratio
7.107.056.674.144.635.37
PB Ratio
8.568.647.874.574.745.18
P/TBV Ratio
8.648.757.914.584.755.20
P/FCF Ratio
-39.0344.4025.0837.4638.31
P/OCF Ratio
-28.3135.7819.5527.5426.91
PEG Ratio
2.210.780.780.780.780.78
EV/Sales Ratio
6.976.906.573.984.475.21
EV/EBITDA Ratio
26.0425.5923.7618.7416.2715.22
EV/EBIT Ratio
28.9628.4026.4421.9218.4716.90
EV/FCF Ratio
-38.1943.7024.1336.1537.18
Debt / Equity Ratio
0.060.010.010.010.010.01
Debt / EBITDA Ratio
0.180.040.030.050.040.04
Debt / FCF Ratio
-0.060.060.060.080.09
Net Debt / Equity Ratio
-0.16-0.15-0.12-0.24-0.09-0.11
Net Debt / EBITDA Ratio
-0.50-0.45-0.36-1.01-0.32-0.34
Net Debt / FCF Ratio
--0.67-0.67-1.30-0.71-0.84
Asset Turnover
-0.960.900.860.850.81
Inventory Turnover
-1.321.361.381.141.08
Quick Ratio
-1.851.981.712.151.85
Current Ratio
-2.853.052.493.503.13
Return on Equity (ROE)
-25.02%23.47%17.68%22.77%23.38%
Return on Assets (ROA)
-14.61%14.03%9.73%12.89%15.68%
Return on Invested Capital (ROIC)
26.98%27.41%26.73%19.30%22.50%25.54%
Return on Capital Employed (ROCE)
-28.10%27.90%19.20%23.70%28.40%
Earnings Yield
2.75%2.81%2.91%3.80%4.61%4.22%
FCF Yield
-2.56%2.25%3.99%2.67%2.61%
Dividend Yield
0.95%1.08%1.65%0.61%0.55%0.56%
Payout Ratio
-37.96%78.68%15.25%11.54%12.68%
Buyback Yield / Dilution
0.41%0.66%1.65%1.19%0.74%0.21%
Total Shareholder Return
1.36%1.74%3.30%1.79%1.29%0.77%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.